Harvard Apparatus Reports 108% Revenue Growth in Q3 2025 Amid Ongoing Losses

Harvard Apparatus Regenerative Technology, Inc. reported its financial results for the third quarter of 2025, revealing a product revenue of $123,000, a significant increase of 108% compared to $59,000 in the same period last year. For the nine months ending September 30, 2025, the company generated $485,000 in product revenue, up 182% from $172,000 in the prior year. Despite this growth, the company continues to face substantial operating losses, reporting a net loss of $1.7 million for the quarter and $5.2 million for the nine-month period, although these figures represent improvements from losses of $1.9 million and $6.4 million, respectively, in the same periods of 2024.

The increase in revenue is attributed to the successful launch of new consumer health products, including dietary supplements marketed primarily in Asia. The company’s strategic shift towards a distributor-based sales model has also contributed to this growth, allowing for reduced sales and marketing expenses, which fell by 83% in the third quarter compared to the previous year. General and administrative expenses decreased by 9% to $1.0 million, reflecting lower insurance premiums and share-based compensation costs.

Operationally, Harvard Apparatus has been focusing on its clinical trial activities, which are essential for the development of its regenerative medicine products. The company has contracted with IQVIA to manage its first clinical trial, which began patient screening in the third quarter of 2023. However, recruitment challenges have arisen due to stringent eligibility criteria and logistical issues, prompting the company to expand its trial sites and enhance patient outreach efforts. As of September 30, 2025, the company had an accumulated deficit of approximately $104.9 million and reported cash and cash equivalents of $1.3 million, which it expects will fund operations into the fourth quarter of 2025.

Looking ahead, Harvard Apparatus acknowledges the need for additional financing to support its ongoing operations and product development. The company is actively seeking capital through various means, including public or private equity offerings and potential collaborations. The ability to secure this funding is critical, as failure to do so may force the company to curtail or cease operations. The management remains optimistic about the future, emphasizing the potential of its regenerative medicine technologies and the growing market for consumer health products.